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Ibaraki virus (IBAV) is a member of the epizootic hemorrhagic disease virus (EHDV) serogroup,
which belongs to the Orbivirus genus of the Reoviridae family. Although EHDV, including IBAV, rep-
resents an ongoing threat to livestock in the world, molecular mechanisms of EHDV replication and
pathogenesis have been unclear. The reverse genetics (RG) system is one of the strong tools to
understand molecular mechanisms of virus replication. Here, we developed a RG system for IBAV
to identify the nonessential region of a minor structural protein, VP6, by generating
VP6-truncated IBAV. Moreover, several tags were inserted into the truncated region to produce
VP6-tagged IBAV. We demonstrated that all VP6-tagged IBAV could replicate in BHK cells in the
absence of any helper VP6 protein. Further, tagged-VP6 proteins were ﬁrst assembled into puncta
in cells infected with VP6-tagged IBAV. Our data suggests that, in order to initiate primary replica-
tion, IBAV VP6 is likely to accumulate in some parts of infected cells to assemble efﬁciently into the
primary replication complex (subcore).
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ibaraki virus (IBAV), a strain of the epizootic hemorrhagic dis-
ease virus (EHDV) serogroup, belongs to the genus Orbivirus, family
Reoviridae. Despite the fact that IBAV is distinguishable from the
eight other serotypes of EHDV, IBAV partially cross-reacts with
antiserum against EHDV serotype 2 (EHDV-2) and thus, the virus
is now classiﬁed as a strain of EHDV-2 [1–3]. EHDV, including
IBAV, is transmitted by blood-feeding midges, Culicoides spp., and
affects wild and domestic ruminants. EHDV is widespread in cer-
vids, especially white-tailed deer, and causes serious disease (epi-
zootic hemorrhagic disease, EHD) with high mortality [4,5].
However, IBAV was ﬁrst reported as the etiological agent of
Ibaraki disease of cattle, which was characterized by fever,
anorexia, salivation, deglutitive disorder and occasionally causes
miscarriage [6–9]. More recently, some strains of EHDV serotypes
6 and 7 also caused outbreaks in cattle from Turkey, Morocco,
the French island of Réunion and Israel, with high morbidity andmortality resulting in signiﬁcant losses in cattle industry [10–16].
Thus, EHDV now represents an ongoing threat to livestock in the
world. Since 2008, EHD has been added to the OIE notiﬁable
disease list (http://www.oie.int/animal-health-in-the-world/
oie-listed-diseases-2015/).
Virus particles of orbiviruses, including IBAV, have three con-
secutive layers of proteins that are organized into two icosahedral
capsids, an outer capsid and an inner capsid (core) [17]. The outer
capsid is composed of two proteins, VP2 and VP5, which are a
receptor-binding protein and a fusion protein, respectively [18].
The core, composed of two major proteins, VP7 and VP3, encloses
the three minor enzymatic proteins VP1 (polymerase), VP4 (cap-
ping enzyme) and VP6 (ATP-dependent RNA helicase) in addition
to viral genome [19–27]. The viral genome consists of
ten-segmented linear double-strand RNA (dsRNA), segment 1 to
segment 10 in decreasing order of size (S1–S10). In addition to
the seven structural proteins described above, the genome also
encodes three or four nonstructural proteins (NS1, NS2, NS3 and
NS4), which are expressed in infected host cells [28–30].
The replication of orbiviruses, occurs in two stages [31]. In the
ﬁrst stage, the outer capsid is removed shortly after cell entry
and the whole core particle is released from the host cell
endosome. The ssRNAs from the 10 genomic segments are then
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compartment and released into the host cell cytoplasm to act as
templates for translation, as well as serving as templates for nega-
tive strand viral RNA synthesis enzymes [32–34]. Newly synthe-
sized transcripts, released from the cores, initiate the primary
replication cycle generating the replicase complex (subcore),
which is composed of VP1, VP3, VP4, VP6 and dsRNA [35–40]. In
the second stage, VP7 is added onto the VP3 layer to form the
stable core particle [35], which subsequently acquires the two
outer capsid proteins, VP2 and VP5, to form mature progeny viri-
ons prior to virus egress [41,42].
To understand each step of virus infection more in detail, such
as dynamic and multi-step viral entry and intercellular transport
of viral proteins, viruses and relevant cellular components are
chemically or genetically labeled with ﬂuorescent probes [43].
Recently, using a reverse genetics (RG) system of BTV, virus parti-
cles were labeled by insertion of tetracysteine tag (TC-tag) into an
outer capsid protein, VP2, to visualize virus attachment and
uncoating [44]. However, to date, any internal proteins of orbi-
viruses, including IBAV, have never been labeled despite the dis-
covery of a nonessential region in BTV VP6 for virus replication
in tissue culture [45].
In this study, based on other orbiviruses’ RG systems [36,40,46–
48], we developed IBAV RG system using in vitro synthesized
ssRNAs from puriﬁed core particle (core transcripts) together with
mammalian expression vectors for core proteins (VP1, VP3, VP4,
VP6 and VP7) and NS2. Using this system, we generated a viable
VP6-truncated IBAV. Importantly, the amino acid (aa) sequence
of aa position 34–82 in IBAV VP6, which was nonessential for
IBAV replication in cell culture system, was not similar to the
one in BTV VP6 (the identity: less than 30%). Moreover, insertion
of tags, such as a TC-tag, into the truncated region of VP6 showed
non-inhibition of virus growth.2. Materials and methods
2.1. Cell lines and virus
BSR cells (BHK-21 subclone) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Nacalai tesque) supplemented
with 4.0% (vol/vol) fetal bovine serum (FBS) (Hyclone). BHK21A11
cells were newly subcloned from BHK-21 cells (purchased from
RIKEN BRC, Cell Bank) and grown in DMEM-4.0% FBS.
IBAV No.2 strain (IBAV-2) was kindly provided by the National
Institute of Animal Health (National Agriculture and Food Research
Organization). The virus stocks were obtained by infecting BSR or
BHK21A11 cells at low multiplicity of infection (MOI) and har-
vested when 100% cytopathic effect (CPE) was evident. Titers of
viral stocks were obtained by plaque assay and expressed as pla-
que formation units per ml (PFU/ml). Viral stocks were stored at
4 C.
2.2. Puriﬁcation of IBAV virus and core particles
IBAV virus and core particles were puriﬁed using polyethylene
glycol (PEG) as described for rotavirus [49,50] with major modiﬁ-
cations. Brieﬂy, BSR cells infected with IBAV-2 at an MOI of 0.05
were harvested at 3 days post-infection and mixed with 8.0%
(wt/vol) of PEG 8000 (Sigma) and 0.5 M of NaCl. The mixture was
incubated for 16 h at 4 C and centrifuged at 15,000g (average
RCF) at 4 C for 1 h. The pellets were lysed in a chilled IBAV lysis
buffer (50 mM Tris–HCl, pH 8.0; 200 mM NaCl; 5 mM EDTA; 0.5%
TritonX-100). Nuclei and insoluble cell debris were removed by
centrifugation at 1400g at 4 C for 15 min. For puriﬁcation of
IBAV particles, the lysate was treated with 1.0% (w/v) N-lauroylsarkosyl at 25 C for 1 h. For puriﬁcation of IBAV core particles,
the lysate was treated with 40 lg/ml of a-chymotrypsin and 1.0%
(w/v) N-lauroyl sarkosyl at 35 C for 1 h. After removal of aggrega-
tions by centrifugation at 6000g at 4 C for 5 min, the particles
were concentrated by centrifugation through a 30% (w/v) sucrose
cushion in 20 mM Tris–HCl (pH 8.0) buffer at 15,000g at 4 C
for 1.5 h. The pellets were re-suspended in 20 mM Tris–HCl (pH
8.0).
Proteins from puriﬁed viruses and cores were analyzed by
denaturing 10% polyacrylamide gel electrophoresis (SDS–PAGE)
followed by staining with Coomassie blue R250.
2.3. Synthesis and puriﬁcation of IBAV ssRNA (core transcripts) in vitro
Core transcripts were synthesized and puriﬁed as described pre-
viously [47] with some modiﬁcations. Brieﬂy, 50 lg of IBAV cores
were incubated at 30 C for 5 h in 500 ll of transcription reaction
mix (40 mM Tris–HCl, pH 8.0; 50 mM NaCl; 4 mM rATP; 2 mM
rGTP; 2 mM rCTP; 2 mM rUTP; 500 lM S-adenosylmethionine;
5 mM dithiothreitol; 8 mM MgCl2; 50 lM MnCl2) supplemented
with 0.2 U/ll RNase inhibitor (Takara). Cores were removed by cen-
trifugation at 15,000g at 4 C for 45 min. The supernatant was col-
lected and incubated with 2 M LiCl at 4 C for 16 h. Core transcripts
were precipitated by centrifugation at 15,000g at 4 C for 15 min,
re-suspended into OPTI-MEM (Life technologies) and puriﬁed using
a standard phenol/chloroform extraction method, which com-
pletely remove the core particles. Puriﬁed core transcripts were
analyzed by electrophoresis on a 0.8% agarose gel in MOPS buffer
in the presence of formaldehyde.
2.4. Plasmids and IBAV T7 transcripts
T7 template plasmids for synthesis of IBAV transcripts used in
RG system were generated as described previously [46]. Brieﬂy,
dsRNA was extracted from puriﬁed core particle using standard
methods and cDNA from each segment ampliﬁed (FLAC). Each seg-
ment was cloned and sequenced. A functional cassette was gener-
ated that introduced a T7 promoter directly upstream and a
restriction enzyme site directly downstream of each genomic
segment.
Modiﬁcation of S9 was generated by site-directed mutagenesis,
using the method as described previously [51]. The mutation
inserted in each modiﬁed T7 S9 plasmid was conﬁrmed by
sequencing.
For IBAV RG system, six mammalian expression vectors,
pCAG-PIBAV2VP1, pCAG-PIBAV2VP3, pCAG-PIBAV2VP4,
pCAG-PIBAV2VP6, pCAG-PIBAV2VP7 and pCAG-PIBAV2NS2, were
generated, as described for BTV RG system [37,40]. Each coding
region of IBAV-2 S1, S3, S4, S9, S7 and S8, encoding VP1, VP3,
VP4, VP6, VP7 and NS2, respectively, was inserted into the mam-
malian expression vector pCAG-PM [52]. The sequence of the cod-
ing region in each expression plasmid was conﬁrmed.
For synthesis of uncapped T7 transcripts, RiboMAX Large Scale
RNA Production System-T7 (Promega) was used according to the
manufacturer’s protocols as described for BTV [37].
2.5. Transfection of cells with core transcripts and/or T7 transcript
Conﬂuent BHK21A11 monolayers were transfected ﬁrst with six
mammalian expression plasmids (0.2 lg each), encoding IBAV VP1,
VP3, VP4, VP6, VP7 and NS2, followed by the second-transfection at
20 h post ﬁrst-transfection with 0.5 lg of IBAV core transcripts
using Lipofectamine 2000 Reagent (Life technologies) as described
previously [40]. At 6 h post second-transfection, the culture med-
ium was replaced with fresh DMEM containing 5% FBS, instead of
1.5-ml overlay consisting of DMEM, 2% FBS, and 1.5% (wt/vol) low
Fig. 1. IBAV cores and IBAV core transcripts. (A) Puriﬁed IBAV virus (left panel) and
IBAV core (right panel) particles stained with 2% uranyl acetate and observed by
electron microscopy. The bar represents 100 nm. (B) IBAV virus and core particles
puriﬁed from BSR cells were resolved by SDS–PAGE. The position of each structural
protein is indicated on the left. (C) Proﬁle of IBAV core transcripts (lane mRNA)
analyzed by denaturing 1% agarose gel. The numbers on the left indicate the lengths
of the marker (lane M) bands in nucleotides. The position of each segment is
indicated on the right.
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1–3 days to allow CPE to appear. The virus titer of recovered IBAV in
supernatants harvested at 24 h post second-transfection was deter-
mined by plaque assay using BHK21A11 cells.
For the synthetic reassortment experiment, 1.0 lg of T7
transcripts were mixed with 1.0 lg of core transcripts and
used for transfection of BSR cells at 20 h post ﬁrst-transfection with
six mammalian expression plasmids. At 2 days post second-
transfection, supernatants were collected. Reassortant viruses in
collected supernatants were plaque-puriﬁed twice in BHK21A11
cells and identiﬁed by the proﬁle of the genomic dsRNAs.
2.6. Virus growth kinetics
For the growth curves of the mutant or control viruses, mono-
layers of BSR cells or BHK21A11 cells were infected at MOI of
0.01. At 0, 12, 24, 48 and 72 h post-infection, cells and supernatant
were harvested together, disrupted by three freeze–thaw cycles
and the total titer was determined by plaque assay using
BHK21A11 cells.
2.7. Detection of tagged VP6 in infected cells
For immunoblotting, BSR cells were infected with VP6-tagged
IBAV at MOI of 0.5 and lysed with IBAV lysis buffer at 24 h
post-infection. For detectionof taggedVP6proteins by immunoblot-
ting techniques, a rabbit anti-DDDDKpolyclonal antibody (MBL) or a
rabbit anti-HA polyclonal antibody (MBL) were used. Proteins were
visualized using alkaline phosphatase-conjugated goat anti-rabbit
immunoglobulin G (IgG) (Sigma) and substrates for alkaline phos-
phatase (Promega).
For in-cell TC-tag detection, BSR cells were infected with the
VP6-tagged IBAV, IBAVd1TC. At 18 h post-infection, TC-tagged
VP6 was detected using FlAsH-EDT2 labeling reagent (Life tech-
nologies) according to the manufacture’s procedures. The ﬂuores-
cent cells were observed using ﬂuorescence microscopy
(KEYENCE, BZ-9000).
For immunoﬂuorescence, BHK21A11 cells were infected with
VP6-tagged IBAV, IBAV2d1HA or IBAVd1Flag, at MOI of 0.5. At 2,
7, 24 and 34 h post-infection, cells were washed once with PBS
and ﬁxed in 4.0% (wt/vol) paraformaldehyde. The cells were per-
meabilized in 0.5% (vol/vol) TritonX-100 (Sigma) in PBS. Staining
was performed using either rabbit anti-HA antibody or rabbit
anti-DDDDK antibody, followed by CF™568 goat anti-rabbit IgG
(Biotium). Nuclei were stained by 40,6-Diamidino-2-Phenylindole
(DAPI) (Nacalai tesque) using standard protocol. Fluorescence
was observed using ﬂuorescence microscopy (KEYENCE, BZ-9000).
2.8. Electron microscopy
Aliquots of puriﬁed viruses and cores were absorbed onto
Formvar/carbon support ﬁlm copper 200 mesh grids (Nisshin
EM) for 1 min, washed with water, and negatively stained with
2% (w/v) uranyl acetate. The grids were examined under an elec-
tron microscope (JEOL, JEM-1400).
3. Results
3.1. Puriﬁcation of IBAV core particles and synthesis of in vitro
transcripts
For synthesis of core transcripts, IBAV-2 core particles were
puriﬁed from BSR cells infected with IBAV-2 virus. As a control,
virus particles were puriﬁed. Puriﬁed core particles were detected
using electron microscopy (Fig. 1A) and protein composition was
veriﬁed by 10% SDS–PAGE gel (Fig. 1B). Although some cell debrisstill remained, IBAV core particles, with 60–65 nm in diameter,
were puriﬁed well using PEG-precipitation method without ultra-
centrifugation step.
Puriﬁed core particles were used for in vitro ssRNA synthesis
(Fig. 1C). Approximately 20 lg of total core transcripts were syn-
thesized from 25 lg of IBAV core particles.
3.2. Recovery of IBAV from core transcripts
To develop a RG system for IBAV, we subcloned BHK-21 cells
using a standard limiting-dilution method, as IBAV formed small
plaques in BSR cells. BHK21A11 cell line was selected as the cells
allowed IBAV-2 to form larger plaques (data not shown).
Although the size of plaques differed between BSR cells and
BHK21A11 cells, there was no signiﬁcant difference between the
virus replication efﬁciency in BSR cells versus BHK21A11 cells
(data not shown).
In our previous report, we demonstrated the existence of a pri-
mary replication cycle in orbivirus infection using a RG system
[37,40,48]. Thus, to increase the chances of recovering infectious
IBAV from core transcripts, six IBAV plasmids expressing the ﬁve
core proteins (VP1, VP3, VP4, VP6 and VP7) and NS2, respectively,
were generated as described in Materials and Methods. BHK21A11
Fig. 2. The recovery of IBAV from core transcripts. BHK21A11 cells were transfected
with 0.5 lg of IBAV-2 core transcripts either in absence (0 seg) or presence (6 seg)
of the ﬁrst-transfection with six expression plasmids, VP1, VP3, VP4, VP6, VP7 and
NS2. As a control (CTRL), BHK21A11 cells were infected with IBAV-2 at MOI of 0.01.
The recovery of virus was shown as the amount of infectious virus (PFU/ml) in
culture media of transfected cells at 24 h after the second-transfection (RG) or
infection (CTRL) (Mean ± SD). The p-value was calculated using Student’s t-
distribution.
A
B C
Fig. 3. Recovery of viable VP6-truncated IBAV from BHK21A11 cells. (A) The second
www.compbio.dundee.ac.uk/jpred/). The aa sequence of IBAV VP6 and the ﬁnal predictio
position. The hidden markov model based prediction (jhmm) and the position speciﬁc sco
a-helix were indicated as ‘E’ and ‘H’, respectively. (B) Genomic dsRNA was puriﬁed fro
position of the corresponding S9 in each VP6-truncated virus. (C) Virus growth kinetics
plaque assay at 0, 12, 24, 48, and 72 h post-infection and plotted as PFU/ml in logarithm
448 E. Matsuo et al. / FEBS Open Bio 5 (2015) 445–453cells were transfected ﬁrst with 0.2 lg each of six IBAV plasmids.
At 20 h post ﬁrst-transfection, the cells were subsequently trans-
fected with 0.5 lg of IBAV core transcripts. In parallel, the cells
were transfected only once with 0.5 lg of IBAV core transcripts.
Only a few plaques, even less plaques than we expected, observed
in cells single-transfected with IBAV core transcripts (data not
shown). Therefore, the efﬁciency of virus recovery was determined
by the amount of infectious virus in a supernatant of transfected
cells, not by the number of plaques formed in transfected cells.
Supernatant of each transfected cells was collected at 24 h post
second-transfection and the virus titer of IBAV in the supernatant
was determined by plaque assay. As a control, BHK21A11 cells
were infected with IBAV at MOI of 0.01 and the amount of infec-
tious virus in supernatant of infected cells was determined by pla-
que assay at 24 h post-infection. Although the titer of IBAV rescued
from core transcripts was lower than that of infection with 0.01
MOI of IBAV (Fig. 2, CTRL column versus 6 seg column), the
ﬁrst-transfection with six IBAV plasmids signiﬁcantly enhanced
virus recovery (Fig. 2, 6 seg column versus 0 seg column). Similar
results were obtained using BSR cells instead of BHK21A11 cellsary structure of IBAV VP6 protein was predicted using Jpred 4 system (http://
n (Jnet) were shown on the top and second lane, respectively. Numbers indicates aa
re matrix based prediction (jpssm) were also shown. The positions of ß-strands and
m infected cells and analyzed by nondenaturing-PAGE. White arrows indicate the
of VP6-truncated viruses IBAVd1 and IBAVd2. Total virus titer was determined by
ic scale (Mean ± SD). As a control, cells were infected with WT IBAV-2.
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cycle is common for all orbiviruses, including IBAV.
3.3. Generation of viable VP6-truncated IBAV
Previously, we demonstrated that BTV VP6 possessed two large
loops (aa 34–130 and aa 183–231) and that the half of the ﬁrst loop
in BTV VP6 (aa 34–94) was not required for viral replication [45].
The secondary structure prediction of IBAV VP6 (Jpred 4, http://
www.compbio.dundee.ac.uk/jpred/) revealed that the region
between aa 31 and 130 and between aa192 and 230 are likely to
form loops (Fig. 3A) despite the low identity of aa sequence in this
region between BTV and IBAV (less than 30%) (data not shown).
Thus, it is possible that truncation of half of the ﬁrst large loop in
IBAV VP6 could still allow IBAV replication in normal cells. To iden-
tify nonessential regions for virus replication in IBAV VP6, we
attempted to generate several VP6-truncated viruses using
BHK21A11 cells.
The four deletions were created in T7 S9 transcript. The mutants
of S9 lacked nucleotides (nt) sequences coding the ﬁrst loop, either
portions (nt 114–242/aa 34–76, d1; nt 114–260/aa 34–82, d2; nt
114–287/aa 34–91, d3) or complete loop region (nt 114–401/aa
34–129, d4) of VP6. To reduce any detrimental effects on the stabil-
ity of the core VP6 domain expressed from mutated T7 S9 tran-
scripts, we substituted the deleted region with the15
mer-sequence coding 5 amino acid residues, Gly–Ala–Gly–Ala–Gl
y (GAGAG) in frame. The residues, GAGAG, are sufﬁcient to stabi-
lize a VP6 protein structure [45].
We previously reported that recovery efﬁciency of BTV from T7
transcripts, which were synthesized in vitro from T7 plasmids, was
considerably lower than that from core transcripts [37,46,47]. InA
C
Fig. 4. Characterization of VP6-truncated viruses in normal BHK21A11 cells. (A) Each 10
ampliﬁed in BHK21A11 cells (P2), followed by ampliﬁcation 9 times (P3–P11) in BSR cells
P6, P11) was analyzed by nondenaturing-PAGE. Position of the corresponding S9 in each
BSR cells infected with each of P11 IBAV were resolved by SDS–PAGE. Position of the c
Electron microscopy of core particles of each VP6-truncated virus. Bar: 100 nm.addition, it is normally more difﬁcult to rescue mutated viruses
than wild-type virus [37]. Thus, in this study, we used a reassort-
ment method to produce mutated IBAV, instead using a complete
T7 system like BTV.
The recovery of viruses containing two mutated S9 RNAs, d1
and d2, was initially screened based on different migration pat-
terns on PAGE gel (Fig. 3B). The identity of S9 mutants was further
conﬁrmed using RT-PCR, followed by sequencing (data not shown).
The majority of the viruses rescued from BHK21A11 cells was reas-
sortants and consisted of d1 or d2 derived from T7 transcripts.
However, IBAV containing other two mutated S9 RNAs, d3 and
d4, has never been rescued from BHK21A11 cells in the absence
of wild-type VP6.
To further assess the replication capability of VP6-truncated
IBAV in normal BHK21A11 cells, the total infectious virus titer
(cell-associated and cell-free virus) was calculated at intervals
and compared to wild-type IBAV (Fig. 3C). The titers of all
VP6-truncated and wild-type IBAV efﬁciently increased through-
out the time course. Although further studies using a complemen-
tary cell line expressing wild-type IBAV VP6 is required to
determine if deletion between aa 34 and 91 or 129 in VP6 is critical
for IBAV replication, at least the region between aa 34 and 82 was
likely to be trivial for IBAV replication in BHK cells.
Viable VP6-truncated viruses were further characterized
(Fig. 4). The proﬁle of genomic dsRNAs extracted from infected
cells in each virus passage (P2, P6, and P11) showed that the trun-
cation was retained in all passaged viruses (Fig. 4A). The presence
of the mutation in each passage was conﬁrmed by sequencing the
corresponding RT-PCR product (data not shown). Moreover, either
an approximately 33 kDa or 32 kDa protein was contained in core
particles, which were puriﬁed from BSR cells infected with each ofB
0 ll of VP6-truncated IBAV plaque-puriﬁed twice from BHK21A11 cells were once
. Pattern of genomic dsRNA puriﬁed from cells infected with IBAVd1 and IBAVd2 (P2,
VP6-truncated virus is indicated with white arrows. (B) Core particles puriﬁed from
orresponding VP6 in each VP6-truncated virus is indicated with black arrows. (C)
450 E. Matsuo et al. / FEBS Open Bio 5 (2015) 445–453P11 mutated virus (Fig. 4B). As both proteins were not contained in
puriﬁed wild-type core particle, they were likely to be truncated
VP6, sizes of which were estimated as 32.7 kDa and 32.0 kDa,
respectively. The data suggests that truncated VP6 was incorpo-
rated with the particle. Interestingly, the truncation of VP6 did
not affect the size of particles (Fig. 4C).A
B
C
Fig. 5. Recovery of viable VP6-tagged IBAV from BHK21A11 cells. (A) Schematic
representation of the changes introduced in IBAV VP6. On the left, the name of
mutation is indicated. Numbers indicate amino acid positions in VP6 where
deletions were introduced. Several amino acid sequences for GAGAG, Flag, HA, and
TC were inserted into a truncated region of the ﬁrst loop. (B) Genomic dsRNA was
puriﬁed from infected cells and analyzed by nondenaturing-PAGE. White arrows
indicate the position of the corresponding S9 in each VP6-tagged virus. (C) Virus
growth kinetics of VP6-tagged viruses IBAVd1Flag, HA and TC. Total virus titer was
determined by plaque assay at 0, 12, 24, 48, and 72 h post-infection and plotted as
PFU/ml in logarithmic scale (Mean ± SD). As a control, cells were infected with WT
IBAV-2.Together all, these results strongly suggest that truncated VP6
proteins are functional in IBAV replication. In addition, the deletion
between aa 34 and 82 in IBAV VP6 does not appear to affect forma-
tion of virus particle.
3.4. Generation of viable VP6-tagged IBAV
In orbiviruses, since ssRNA sequences of the both ends of each
segment, including both non-coding region and a part of coding
region, are essential for genome packaging [37], it is impossible
to insert tags into the end of the proteins to label the virus parti-
cles. However, an unimportant region of VP6, which was partially
identiﬁed in this study, could allow us to genetically label IBAV
particles using RG system by inserting several probes into that
region in frame. To determine if the loop region in VP6 could toler-
ate the insertion of several tags, three VP6-tagged viruses wereA
B
C
Fig. 6. Characterization of VP6-truncated viruses in normal BHK21A11 cells. (A)
Either Flag or HA-tagged VP6 were detected in BSR cells infected with VP6-tagged
IBAV by immunoblot analysis. As a control, IBAVd1 or IBAVd1TC were infected to
the cells. Arrowheads indicate the detected tagged proteins. (B) TC-tagged VP6 was
detected in the IBAVd1TC-infected BSR cells using FlAsH-EDT2 labeling reagent.
Note that some TC-VP6 proteins were detected as puncta (white arrowheads). (C)
After 10 times passage of each VP6-tagged IBAV, pattern of genomic dsRNA puriﬁed
from cells infected with IBAVd1Flag, HA and TC (P2 and P10) was analyzed by
nondenaturing-PAGE. Position of the corresponding S9 in each VP6-tagged virus is
indicated with white arrows.
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Flag-tag (YKDDDDK), HA-tag (YPYDVPDYA) or TC-tag (CCPGCC)
in frame (Fig. 5A). All three VP6-tagged IBAV, IBAVd1Flag,
IBAVd1HA and IBAVd1TC, were successfully generated by IBAV
RG system using BHK21A11 cells (Fig. 5B).
To further conﬁrm the viability of VP6-tagged IBAV, BHK21A11
cells were infected at MOI of 0.01 with each of VP6-tagged viruses
and harvested at 12, 24, 48 and 72 h post-infection. The titers of all
VP6-tagged viruses increased throughout the time course, similar
to that of the wild-type IBAV (Fig. 5C), suggesting that tagged
VP6 was functional in IBAV replication.
Each of tagged VP6 proteins was detected in cells infected with
each VP6-tagged virus (Fig. 6A and B). Flag or HA-tagged VP6 with
expected size (33 kDa) were detected by anti-DDDDK antibody
and anti-HA antibody, respectively (Fig. 6A) and TC-tagged VP6
was successfully labeled with FlAsH reagent at 18 h
post-infection (Fig. 6B). Note that some of TC-tagged VP6 proteins
formed puncta. In addition, the incorporation of tagged VP6 with
puriﬁed IBAV particle was conﬁrmed using antibodies against tags
(data not shown).
To access the stability of inserted tags, each VP6-tagged virus
was continuously passaged 10 times and dsRNA proﬁles of passage
2 (P2) and passage 10 (P10) were conﬁrmed (Fig. 6C). The presence
of the mutation in each passage was also conﬁrmed by sequencing
the corresponding RT-PCR product (data not shown).
3.5. Translocation of VP6 in early infection of IBAV
Despite decades of attempts to clarify the actual role of VP6, the
exact function of BTV VP6 in BTV biology still remains to be
addressed. Our data demonstrated that VP6 with substitution ofA
B
Fig. 7. Translocation of tagged VP6 in the infected cells. (A) Flag-tagged VP6 was
detected using anti-rabbit DDDDK antibody at 2, 7, 24, and 36 h post-infection with
IBAV d1Flag at MOI of 0.5. Nuclei were stained with DAPI. Arrowheads indicate
puncta formation of VP6. (B) Magniﬁed images of BHK21A11 cells infected with
either IBAVd1Flag (left) or IBAVd1HA (right) at 7 h post-infection. Nuclei were
stained with DAPI. Arrowheads indicate puncta formation of VP6. Fluorescent
images were merged with bright ﬁeld images.region between aa 34 and 76 with tags were still functional and
could act exactly same as wild-type VP6. Thus, VP6-tagged IBAV
could allow us to detect the precise location of VP6 in infected
cells, as well as in virus particle.
Interestingly, TC-tagged IBAV formed puncta in infected cells at
18 h post-infection (Fig. 6B). To further conﬁrm if VP6 forms
puncta in early infection, BHK21A11 cells were infected with
VP6-tagged IBAV and at 2, 7, 24 and 36 h post-infection (Fig. 7).
At 7 h post-infection, Flag-tagged VP6 already assembled into
puncta, while the proteins were detectable throughout the cytosol
at 24 h and 36 h post-infection (Fig. 7A). HA-tagged VP6 also
assembled into puncta at 7 h post-infection in BHK21A11 cells
(Fig. 7B right panel). The same results were obtained using BSR
cells (data not shown). As orbivirus VP6 is likely to be important
for assembly of the primary replicase complex [37,40], these data
suggest that VP6 may be necessary to be concentrated in cytosol
of the infected cells in order to initiate primary replication
efﬁciently.
4. Discussion
Despite the potential for devastating economic impact on the
livestock industry, studies on EHDV, including IBAV, replication
and pathogenesis have been hampered due to lack of methods
for the rescue of infectious virus from cloned nucleic acid (RG sys-
tem). Therefore, until now, it has not been possible to carry out
introduction of targeted mutations into replicating virus genomes.
We presented here a method to undertake RG experiments with
IBAV. In particular, we ﬁrst generated viable VP6-tagged IBAV
and demonstrated translocation of IBAV VP6 in real IBAV
replication.
Our previous studies on replication of orbiviruses, such as BTV
and African horse sickness virus (AHSV) [36,37,40], indicated that
the primary replication step was common to the replication of all
orbiviruses. Our RG data conﬁrmed its existence in EHDV.
Although the replication efﬁciency of IBAV in BHK cells was almost
equivalent to that of BTV or AHSV, the recovery efﬁciency of IBAV
RG system was much lower than that of BTV or AHSV RG system.
IBAV is less virulent than BTV and AHSV (ie mortality 20% versus
over 70%) [17,53,54]. In addition, most EHDV, including IBAV,
cause subclinical infection in cattle [55–57], in which virus replica-
tion could be suppressed. Thus, it is possible that some unknown
factors, which efﬁciently initiate primary replication soon after
second-transfection of core transcripts, could be lacking in current
IBAV RG system. For development of the complete plasmid-based
T7 RG system for IBAV, some modiﬁcation is required. RG system
for hepatitis C virus requires enough viral polymerase activity to
trigger genome replication [58–61]. Polymerase activity of IBAV
may be lower than those of BTV and AHSV.
The truncation of a region between aa 34 and 94 in BTV VP6 still
allowed the VP6-truncated BTV to replicate in absence of wild-type
VP6 [45]. On the other hand, our data showed that a deletion of a
region between aa 34 and 82 in VP6 still allowed VP6-truncated
IBAV to replicate in absence of wild-type VP6 but not a deletion
of a region between aa 34 and 91 (d3) in the protein. A comple-
mentary cell line, BSR-VP6, was used for rescue of VP6-truncated
BTV, whereas only normal BHK21A11 or BSR cells were used for
rescue in this study. Thus, it is still possible that enough amount
of wild-type VP6 could be required only for the ﬁrst recovery of
d3 virus and, once the virus recovered, d3 can replicate in the
absence of wild-type VP6. Another possibility is that the essential
region in VP6 for IBAV replication could be different from that
for BTV replication. Interestingly, aa sequences of the loop regions
in VP6 are variable among orbiviruses whereas non-coiled regions
in VP6 were highly conserved (Matsuo et al. unpublished data).
452 E. Matsuo et al. / FEBS Open Bio 5 (2015) 445–453This variation of residues in ﬂexible loop might be an important
factor to cause differences in initiation of primary replication.
Nevertheless, further studies are required to determine whether
the failure of d3 recovery was due to lack of essential region in
VP6, which includes a region between aa 82 and 91, for IBAV repli-
cation or just a technical issue.
VP6-trancated IBAV and VP6-labeled IBAV were likely to repli-
cate even better than wild-type IBAV, especially after 48 h
post-infection. The deletion between aa 34 and 82 of VP6 may
affect the efﬁciency of IBAV replication. As well as VP6, a nonstruc-
tural protein, NS4, which plays an important role in virus-host
interaction, is also encoded in S9 segment [28]. Thus, the partially
deletion of VP6 results in a deletion of NS4. Although further stud-
ies are required, it is possible that the deletion of either a part of
VP6 or NS4 changed the cytotoxicity of mutated IBAV.
Orbivirus, including EHDV, is unique among the Reoviridae fam-
ily in encoding VP6, a protein with nucleoside triphosphatase, RNA
binding, and helicase activity in vitro [20,25,62]. In addition, we
recently reported that BTV VP6 possesses an essential role in pri-
mary replication and a plausible role in RNA packaging during core
assembly as well [37,40,63]. A nonstructural protein, NS2, is the
main component of viral inclusion bodies (VIB) in infected cells
where assembly of core particle takes place [64–67]. Thus, it is pos-
sible that NS2 interacts with VP6 and maybe other viral proteins to
form VIB soon after translated. Together with these facts, VP6
should translocate into VIB in early stage of infection. Our data
clearly showed that VP6 protein assembled into puncta, which
resembled orbivirus VIB [17], in early stage of IBAV infection.
Although further studies, such as co-localization assay with NS2,
should be necessary, to initiate the primary replication, IBAV VP6
is likely to ﬁrst translocate into VIB to assemble into the primary
replication complex, subcore.
To date, it has not been possible to determine a precise
location of VP6 within the core as inside of the particles were com-
pletely occupied with internal virus proteins, including VP6, and
genome (Matsuo, Noda, Kawaoka and Roy unpublished data). Our
data showed that tagged-VP6 did not affect formation of core par-
ticle. However, the truncation of VP6 could make some spaces
inside of the particle to allow us to identify each of elements in
the core.
Recently, live cell imaging techniques have been developed in
several viruses, including BTV [43,44]. Insertion of TC-tag into a
putative exposed region in an outer capsid protein of BTV, VP2,
successfully made infectious BTV particles visible and detectable
at virus binding stage in replication [44]. In this study, using newly
developed RG system, we demonstrated the insertion of tags into
unimportant region of IBAV VP6 to visualize the localization of
VP6 after transcription step. In addition, our data suggested that
several tags in VP6 should allow us to visualize the inside of the
particle. TC-labeling of outer capsid combined with labeling of core
proteins should visualize uncoating step in near future.
Overall, the data presented in this report demonstrate the
development of EHDV RG system, particular, the ubiquitous exis-
tence of unimportant region in orbivirus VP6. Together with tech-
niques already developed in other orbiviruses, it should be possible
to deﬁne precisely the mechanisms of the virus replication at a
ﬁner level. In addition, our data would contribute to clarify the
similarity and differences between orbiviruses and other viruses
of family Reoviridae in virus replication.
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